What is the equity of Merus this year?
Merus has equity of 356.34 M USD this year.
Merus Equity 2024
Merus Equity
356.34 M USD
Ticker
MRUS
ISIN
NL0011606264
WKN
A2AKFX
In 2024, Merus's equity was 356.34 M USD, a 44.21% increase from the 247.1 M USD equity in the previous year.
Merus Aktienanalyse
What does Merus do?
Merus NV is a Dutch biotechnology company specialized in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2003 by Ton Logtenberg and Piet Gros and is headquartered in Utrecht. Merus' business model is based on the development of bispecific antibodies, which can bind to two different target structures simultaneously. These antibodies can specifically attack and destroy tumor cells by minimizing their binding to healthy cells, providing Merus with a high potential for cancer therapy and other diseases. The company is divided into two main divisions: Merus BV and Merus US Inc. Merus BV specializes in the development of bispecific antibodies and operates its own manufacturing facility in Utrecht, while Merus US Inc. focuses on the clinical development of cancer immunotherapies. Merus offers a variety of products, including Bispecific Antibodies for Multiple Targets (BAMTs), Multi-specific Antibodies (MSAs), TrioBody platform, and Smart-chemotherapy platform. The BAMT program aims to develop bispecific antibodies that can bind to multiple target structures simultaneously, enhancing their effectiveness against tumor cells. The company's MSA products aim to introduce a bispecific antibody system with specialized drainage function to enhance the efficiency of cancer treatments. Merus' TrioBody platform represents a form of bispecific antibodies specifically tailored to cells in tumors, providing a higher efficacy in destroying tumor cells compared to conventional antibodies. Merus' Smart-Chemotherapy platform aims to increase the efficiency of chemotherapy drugs by delivering the medication specifically to tumor cells, maximizing its effect on tumor cells while minimizing its effect on normal cells. The company has entered into various partnerships and collaborations with other companies to advance its research and development in the field of cancer immunotherapy. In 2018, Merus signed an agreement with Incyte, granting Incyte the right to use Merus' bispecific antibody platform for cancer treatment. Additionally, Merus has formed strategic alliances with other biotechnology companies such as Jazz Pharmaceuticals and Loxo Oncology to further develop in various areas of cancer immunotherapy. Merus is committed to continue investing in research and development of its antibody technology to increase the effectiveness of cancer treatments and provide patients worldwide with new therapies to combat cancer. Merus ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Merus's Equity
Merus's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Merus's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Merus's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Merus's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Merus’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Merus stock
What was the equity of Merus compared to the previous year?
The equity of Merus has increased/decreased by 44.21% increased compared to the previous year.
What impact does a high equity have on investors of Merus?
A high equity is advantageous for investors of Merus as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Merus?
A low equity can be a risk for investors of Merus, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Merus affect the company?
An increase in equity of Merus can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Merus affect the company?
A reduction in equity of Merus can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Merus?
Some factors that can affect the equity of Merus include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Merus so important for investors?
The equity of Merus is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Merus take to change the equity?
To change equity, Merus can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Merus pay?
Over the past 12 months, Merus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Merus is expected to pay a dividend of 0 USD.
What is the dividend yield of Merus?
The current dividend yield of Merus is .
When does Merus pay dividends?
Merus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Merus?
Merus paid dividends every year for the past 0 years.
What is the dividend of Merus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Merus located?
Merus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Merus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Merus from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
When did Merus pay the last dividend?
The last dividend was paid out on 9/13/2024.
What was the dividend of Merus in the year 2023?
In the year 2023, Merus distributed 0 USD as dividends.
In which currency does Merus pay out the dividend?
The dividends of Merus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Merus
Our stock analysis for Merus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
